Wave Life Sciences Ltd.

Good morning and welcome to the Wave Life Sciences third quarter 2022 financial results conference call. At this time, all participants are on a listen-only mode. As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Roush, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.

Thank you, Operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's third quarter 2022 financial results. Joining me in the room today are Dr. Paul Bono, President and Chief Executive Officer, Anne-Marie Lee-Kwai Chung, Chief Development Officer, and Kyle Moran, Chief Financial Officer. The press release issued this morning and the slide presentations to accompany this webcast are available in the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings, including our annual report on Form 10-K for the year ended December 31st, 2021, and our quarterly report on Form 10-Q for the quarter ended September 30th, 2022. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul.

Thanks, Kate. Good morning, and thank you all for joining us. I will start today's call with some recent highlights and then introduce our Chief Development Officer, Anne-Marie Lee-Quintron. Anne-Marie will provide updates on our most advanced therapeutic program, and finally, Kyle will discuss our financials. 2022 has been a pivotal year for WAVE. At the start of this year, we said we would deliver data updates from three separate clinical trials, as well as advance an entirely new modality through candidate nomination. To date, we have delivered the first two clinical data updates, including results from our ongoing C9ALS FDD study, showing potent and durable target engagement with WVE004, and most recently, the first clinical data from our select HD trial for Huntington's disease. indicating allele-selective target engagement with WBE003. Both these datasets validated our novel PN chemistry and supported the clinical translation of our discovery and development platform. We are on track to deliver clinical data from our Duchenne Muscular Dystrophy open-label clinical trial later this quarter. By designing oligonucleotides to efficiently harness ADAR enzymes, we have unlocked entirely new biology with our platform. In the third quarter, we selected our first RNA editing or AMER development candidate, WVE006, for Alpha-1 antitrypsin deficiency, or AATD. In September, we held a virtual event spotlighting the biology of this disease, our RNA editing therapeutic approach, and the existing unmet needs that we hope to address with WVE006. We were joined by a well-known clinical expert in the treatment of AATD, Dr. Kyle Hogarth, who shared perspectives on the current treatment landscape and the benefit of having one therapy, such as OO6, to address both liver and lung manifestations of AATD without permanent genetic alteration. I invite you to tune into the replay on our website if you missed this live event. Preclinical data for WVE006 were also presented for the first time in a scientific setting at the Allogonucleotide Therapeutic Society meeting last month. At OTS and other recent forums, we continue to highlight the broad applicability of WAVE's unique oligonucleotides and backbone chemistry. This includes using amers to upregulate genes and applying prism chemistry to siRNA to achieve remarkably potent and durable silencing in preclinical models. This coming week, our chief technology officer, Chandra Varghese, will be presenting these data and other results that demonstrate the versatility of WAVE's platform at a special symposium at the Black Plank Institute alongside other innovators in oligonucleotide chemistry. Before turning the call over to our Chief Development Officer, Anne-Marie, I would like to take this time to briefly introduce her to those listening in. Anne-Marie joined WAVE at the beginning of this year as a senior leader in our clinical development organization. Previously, she spent eight years at Roche holding leadership positions on increasing responsibility in global drug development and global program leadership, within the neurology and rare disease therapeutic areas, particularly in Huntington's disease. We were very excited to have Anne-Marie rise to her expanded role in September, as we know her deep experience across clinical development, commercial activities, as well as regulatory and compliance will be critical to WAVE as we advance our innovative pipeline. And with that, I'll now turn the call over to Anne-Marie.